Parkman Healthcare Partners LLC Takes $841,000 Position in Pulmonx Corporation $LUNG

Parkman Healthcare Partners LLC purchased a new stake in Pulmonx Corporation (NASDAQ:LUNG) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 646,564 shares of the company’s stock, valued at approximately $841,000.

A number of other large investors also recently bought and sold shares of LUNG. ExodusPoint Capital Management LP purchased a new position in Pulmonx during the fourth quarter worth approximately $4,312,000. Bank of America Corp DE lifted its position in shares of Pulmonx by 60.3% during the 1st quarter. Bank of America Corp DE now owns 1,166,826 shares of the company’s stock valued at $1,505,000 after buying an additional 439,027 shares in the last quarter. BlackRock Inc. acquired a new stake in Pulmonx in the 2nd quarter valued at $1,147,000. Vestal Point Capital LP purchased a new stake in Pulmonx in the 3rd quarter worth $1,345,000. Finally, State Street Corp raised its position in Pulmonx by 3.6% during the fourth quarter. State Street Corp now owns 821,217 shares of the company’s stock worth $1,815,000 after acquiring an additional 28,813 shares during the period. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Price Performance

Pulmonx stock opened at $2.28 on Tuesday. The stock has a market cap of $97.93 million, a P/E ratio of -1.97 and a beta of 0.28. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95. The company has a 50-day moving average price of $1.63 and a 200 day moving average price of $1.51. Pulmonx Corporation has a 12-month low of $1.13 and a 12-month high of $2.89.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%.The firm had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. Sell-side analysts anticipate that Pulmonx Corporation will post -1.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Thursday, April 30th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Monday, July 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.